Functional Selectivity and Partial Efficacy at the Monoamine Transporters: A Unified Model of Allosteric Modulation and Amphetamine-Induced Substrate Release - PubMed

Affiliations

• PMID: 30567955
• DOI: 10.1124/mol.118.114793

Review

Functional Selectivity and Partial Efficacy at the Monoamine Transporters: A Unified Model of Allosteric Modulation and Amphetamine-Induced Substrate Release

Peter S Hasenhuetl et al. Mol Pharmacol. 2019 Mar.

Abstract

All clinically approved drugs targeting the plasmalemmal transporters for dopamine, norepinephrine, and serotonin act either as competitive uptake inhibitors or as amphetamine-like releasers. Monoamine transporter (MAT) ligands that allosterically affect MAT-mediated substrate uptake, release, or both were recently discovered. Their modes of action have not yet been explained in a unified framework. Here, we go beyond competitive inhibitors and classic amphetamines and introduce concepts for partial efficacy at and allosteric modulation of MATs. After we elaborate on a kinetic account for amphetamine action, we provide an explanation for partial release (i.e., the observation that some amphetamines are less efficacious than others in inducing monoamine efflux). We then elucidate mechanisms of allosteric inhibition and stimulation of MATs, which can be functionally selective for either substrate uptake or amphetamine-induced release. These concepts are integrated into a parsimonious kinetic framework, which relies exclusively on physiologic transport modes (without any deviation from an alternating access mechanism). The model posits cooperative substrate and Na⁺ binding and functional selectivity by conformational selection (i.e., preference of the allosteric modulators for the substrate-loaded or substrate-free states of the transporter). Thus, current knowledge about the kinetics of monoamine transport is sufficiently detailed to provide a quantitative description of the releasing action of amphetamines, of substrate uptake, and of selective modulation thereof by allosteric modulators.

Similar articles

• A kinetic account for amphetamine-induced monoamine release.

  Hasenhuetl PS, Bhat S, Mayer FP, Sitte HH, Freissmuth M, Sandtner W. Hasenhuetl PS, et al. J Gen Physiol. 2018 Mar 5;150(3):431-451. doi: 10.1085/jgp.201711915. Epub 2018 Feb 9. J Gen Physiol. 2018. PMID: 29439119 Free PMC article.

• Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action.

  Seidel S, Singer EA, Just H, Farhan H, Scholze P, Kudlacek O, Holy M, Koppatz K, Krivanek P, Freissmuth M, Sitte HH. Seidel S, et al. Mol Pharmacol. 2005 Jan;67(1):140-51. doi: 10.1124/mol.67.1.. Mol Pharmacol. 2005. PMID: 15615700

• Overview of Monoamine Transporters.

  Aggarwal S, Mortensen OV. Aggarwal S, et al. Curr Protoc Pharmacol. 2017 Dec 20;79:12.16.1-12.16.17. doi: 10.1002/cpph.32. Curr Protoc Pharmacol. 2017. PMID: 29261228 Free PMC article. Review.

• Designing modulators of monoamine transporters using virtual screening techniques.

  Mortensen OV, Kortagere S. Mortensen OV, et al. Front Pharmacol. 2015 Sep 29;6:223. doi: 10.3389/fphar.2015.00223. eCollection 2015. Front Pharmacol. 2015. PMID: 26483692 Free PMC article. Review.

Cited by

• Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters.

  Bhat S, Guthrie DA, Kasture A, El-Kasaby A, Cao J, Bonifazi A, Ku T, Giancola JB, Hummel T, Freissmuth M, Newman AH. Bhat S, et al. ACS Pharmacol Transl Sci. 2020 Aug 28;4(2):503-516. doi: 10.1021/acsptsci.0c00102. eCollection 2021 Apr 9. ACS Pharmacol Transl Sci. 2020. PMID: 33860180 Free PMC article.

• Unlocking the Potential of High-Quality Dopamine Transporter Pharmacological Data: Advancing Robust Machine Learning-Based QSAR Modeling.

  Lee KH, Won SJ, Oyinloye P, Shi L. Lee KH, et al. bioRxiv [Preprint]. 2024 Mar 11:2024.03.06.583803. doi: 10.1101/2024.03.06.583803. bioRxiv. 2024. PMID: 38558976 Free PMC article. Preprint.

• How to rescue misfolded SERT, DAT and NET: targeting conformational intermediates with atypical inhibitors and partial releasers.

  Bhat S, Newman AH, Freissmuth M. Bhat S, et al. Biochem Soc Trans. 2019 Jun 28;47(3):861-874. doi: 10.1042/BST20180512. Epub 2019 May 7. Biochem Soc Trans. 2019. PMID: 31064865 Free PMC article. Review.

• Identification of the potassium-binding site in serotonin transporter.

  Hellsberg E, Boytsov D, Chen Q, Niello M, Freissmuth M, Rudnick G, Zhang YW, Sandtner W, Forrest LR. Hellsberg E, et al. Proc Natl Acad Sci U S A. 2024 Apr 30;121(18):e2319384121. doi: 10.1073/pnas.2319384121. Epub 2024 Apr 23. Proc Natl Acad Sci U S A. 2024. PMID: 38652746 Free PMC article.

• Community guidelines for GPCR ligand bias: IUPHAR review 32.

  Kolb P, Kenakin T, Alexander SPH, Bermudez M, Bohn LM, Breinholt CS, Bouvier M, Hill SJ, Kostenis E, Martemyanov KA, Neubig RR, Onaran HO, Rajagopal S, Roth BL, Selent J, Shukla AK, Sommer ME, Gloriam DE. Kolb P, et al. Br J Pharmacol. 2022 Jul;179(14):3651-3674. doi: 10.1111/bph.15811. Epub 2022 Mar 27. Br J Pharmacol. 2022. PMID: 35106752 Free PMC article. Review.

Publication types

MeSH terms

Substances